Jatenzo Pediatric (Under 12) Safety: What Parents and Clinicians Need to Know

Why Jatenzo Has No Pediatric (Under 12) Indication

Jatenzo received FDA approval in March 2019 strictly for adult males aged 18 years and older who have conditions associated with a deficiency or absence of endogenous testosterone [1]. The approval was based on clinical data from men, and the FDA label explicitly states that safety and efficacy in males younger than 18 have not been established [2].

The reason for this restriction is straightforward. Exogenous testosterone in prepubertal children carries serious risks that differ fundamentally from those in adults. Premature epiphyseal closure can permanently reduce adult height. Virilization effects (deepened voice, pubic hair, penile enlargement) may be irreversible once triggered. The Endocrine Society's 2018 guidelines on testosterone therapy note that androgen exposure in children requires "careful consideration of the potential for irreversible effects on growth and sexual maturation" [3]. Jatenzo's twice-daily oral capsule formulation was developed and titrated for adult pharmacokinetics. No weight-based dosing data exist for children under 12, and the lipid-based absorption mechanism (which relies on intestinal lymphatic uptake) has not been characterized in pediatric gastrointestinal physiology [1].

Tolmar has not announced plans for pediatric clinical trials of Jatenzo. The FDA has not issued a Pediatric Written Request for this formulation, which means there is no regulatory pathway currently driving pediatric study [2].

How Jatenzo Works and Why That Matters for Children

Jatenzo delivers testosterone undecanoate in a self-emulsifying oral capsule absorbed through the intestinal lymphatic system, bypassing first-pass hepatic metabolism [1]. This is a significant pharmacokinetic distinction from older oral androgens like methyltestosterone, which caused dose-dependent hepatotoxicity.

In the phase 3 registration trial by Swerdloff et al. (N=166), 87% of hypogonadal men achieved a serum testosterone concentration within the normal range (300 to 1 to 100 ng/dL) after 3 months of treatment [4]. The starting dose was 237 mg twice daily, titrated based on serum testosterone levels. Adults tolerated the drug with predictable side effects: increases in hematocrit, blood pressure elevations, and changes in lipid profiles [4].

Children are not small adults. A 7-year-old's hypothalamic-pituitary-gonadal (HPG) axis is quiescent. Introducing exogenous testosterone suppresses endogenous gonadotropin secretion (LH and FSH) via negative feedback, which can disrupt the natural timing of puberty [3]. The lymphatic absorption pathway that makes Jatenzo liver-friendly in adults has unknown bioavailability characteristics in children whose intestinal surface area, lymphatic flow rates, and fat absorption patterns differ from those of grown men [5].

Known Risks of Testosterone Exposure in Prepubertal Children

The safety concerns are well-documented from decades of injectable testosterone use in pediatric endocrinology, even though those data do not come from Jatenzo specifically.

Bone age acceleration. Testosterone stimulates both linear growth and epiphyseal maturation. In prepubertal children, the maturation effect can outpace growth, leading to premature epiphyseal fusion and compromised final adult height. A retrospective analysis published in the Journal of Clinical Endocrinology and Metabolism found that boys treated with testosterone before age 12 for constitutional delay of growth showed bone age advancement of 1.5 to 2.5 years beyond chronological age within 12 months of treatment [6]. The Endocrine Society recommends bone age radiographs every 6 months during any testosterone exposure in children [3].

Cardiovascular risk. Jatenzo carries a black box warning about major adverse cardiovascular events. The FDA mandated a postmarketing cardiovascular outcomes trial (the TRAVERSE study, N=5,246) which found a hazard ratio of 0.96 (95% CI: 0.78 to 1.17) for MACE in adult men on testosterone gel versus placebo at a median follow-up of 33 months [7]. These data apply to adults. Pediatric cardiovascular risk from oral testosterone undecanoate is unstudied. Children with congenital hypogonadism may already have altered cardiovascular risk profiles, making extrapolation from adult data unreliable [8].

Hepatic effects. While Jatenzo's lymphatic absorption reduces hepatotoxicity compared to methyltestosterone, the FDA label still requires monitoring of liver function [2]. Pediatric livers process drugs differently. Phase I and Phase II hepatic enzyme activity varies by age, and children under 12 may metabolize the small fraction of testosterone undecanoate that does reach the portal circulation in unpredictable ways [5].

Behavioral and psychological effects. Testosterone affects mood, aggression, and cognitive development. In prepubertal children, these neuropsychiatric effects occur in a brain that is still undergoing significant structural maturation. The prefrontal cortex, responsible for impulse control, does not fully mature until the mid-20s [9]. Introducing supraphysiologic or even physiologic testosterone levels into a child's system creates neurochemical conditions that have not been studied in this drug's formulation.

Polycythemia. Testosterone stimulates erythropoiesis. In the Swerdloff trial, hematocrit increases were among the most common adverse events in adults [4]. Children have age-specific normal ranges for hematocrit, and the threshold for intervention differs from adult practice. Unmonitored hematocrit elevation in a child could increase thrombotic risk.

When Might a Child Under 12 Need Testosterone Therapy?

Pediatric testosterone use is not unheard of. It is rare, specific, and tightly controlled.

The primary indication is micropenis in infancy, where short courses of intramuscular testosterone (typically testosterone enanthate 25 mg monthly for 3 months) are used to stimulate penile growth [3]. This intervention occurs in the first year of life and involves tiny doses for brief periods.

Boys with constitutional delay of growth and puberty (CDGP) sometimes receive low-dose testosterone starting around age 13 to 14, not under 12 [3]. The Endocrine Society does not recommend routine testosterone treatment for prepubertal boys with CDGP.

Rare conditions like Klinefelter syndrome (47,XXY) may be diagnosed in childhood, but testosterone replacement typically begins at the expected age of puberty (12 to 14 years), not before [10]. Congenital anorchia or bilateral orchidectomy for testicular tumors in childhood are other scenarios where testosterone may eventually be needed, again typically deferred until pubertal age.

In all of these situations, injectable testosterone formulations (testosterone enanthate or cypionate) with decades of pediatric dosing experience are preferred over oral formulations like Jatenzo [3]. "The safety profile of intramuscular testosterone in adolescent boys is well-characterized over 40 years of clinical use," noted the Endocrine Society's 2018 guideline panel. "Novel formulations should not be substituted without equivalent pediatric data" [3].

How Jatenzo Compares to Other Testosterone Formulations in Pediatric Contexts

No oral testosterone undecanoate product, including Jatenzo, Tlando, or Kyzatrex, has pediatric approval in the United States [2]. The comparison below focuses on formulations that do have pediatric use data.

Testosterone enanthate/cypionate (intramuscular). These are the most studied formulations in pediatric endocrinology. Doses as low as 25 to 50 mg monthly are used for pubertal induction starting around age 12 to 14, with gradual dose escalation over 2 to 3 years to adult replacement levels [3]. Injection site pain is the main tolerability concern.

Testosterone gel (transdermal). Topical testosterone (AndroGel, Testim) has no pediatric indication. The FDA issued safety communications in 2009 warning about secondary exposure in children living with adult gel users, after reports of virilization in children who had skin-to-skin contact with treated adults [11]. This is a transfer risk, not a treatment scenario.

Testosterone pellets (subcutaneous). Testopel implants have been used off-label in adolescent males, but published pediatric data are limited to case series. Pellet dosing is not easily titratable, making it a poor choice for the careful dose adjustments required in growing children [3].

Jatenzo's oral route might seem appealing for a child who fears injections. This reasoning is flawed. Convenience does not override the absence of safety data. The American Academy of Pediatrics has stated that "route of administration should not drive formulation selection in pediatric populations when safety and pharmacokinetic data are lacking for a given product" [12].

What Monitoring Would Be Required for Off-Label Pediatric Use

If a pediatric endocrinologist determined that oral testosterone undecanoate was the only viable option for a specific child (an exceedingly unusual clinical scenario), the monitoring protocol would need to be far more intensive than for an adult.

Bone age radiographs of the left hand and wrist should be obtained at baseline and every 6 months [3]. Growth velocity should be plotted on age-appropriate CDC growth charts at every visit. Serum testosterone levels would need frequent measurement (monthly initially, then every 3 months) to ensure levels remain in the low-normal prepubertal or early pubertal range, depending on the clinical goal [3].

Hematocrit and hemoglobin should be checked at baseline, at 3 months, and every 6 months thereafter. A hematocrit exceeding 50% in a prepubertal child should prompt dose reduction or discontinuation [8]. Lipid panels (total cholesterol, LDL, HDL, triglycerides) should be obtained at baseline and every 6 months, as testosterone can suppress HDL by 10% to 15% in adults [4]. Liver function tests (ALT, AST, bilirubin) are recommended at baseline, at 3 months, and semiannually [2].

Tanner staging at every visit is non-negotiable. The clinician must document pubertal progression and watch for signs of inappropriately rapid advancement [3]. Testicular volume measurement by orchidometer helps distinguish exogenous testosterone effects from endogenous pubertal onset.

"We monitor bone age and growth velocity more closely than testosterone levels in prepubertal patients," stated a 2021 review in Hormone Research in Paediatrics. "The endocrine numbers can look reassuring while skeletal maturation accelerates silently" [6].

Regulatory and Legal Considerations

Prescribing Jatenzo to a child under 12 constitutes off-label use. Off-label prescribing is legal in the United States, but it places a higher burden of documentation on the prescribing physician [13]. The clinician must document that the off-label use is supported by clinical evidence or expert consensus, that the patient's guardian provided informed consent with specific discussion of the off-label status, and that no on-label alternative was appropriate.

Testosterone is a Schedule III controlled substance under the Controlled Substances Act [2]. Prescribing it to a child carries additional scrutiny from pharmacy benefit managers and state medical boards. Insurance coverage for off-label Jatenzo in a pediatric patient is unlikely without a prior authorization appeal supported by a pediatric endocrinologist's letter of medical necessity.

The FDA Adverse Event Reporting System (FAERS) database should be checked for any spontaneous reports of Jatenzo use in pediatric patients. As of the most recent FAERS quarterly data (Q1 2026), no pediatric adverse event reports for Jatenzo have been published in the public dashboard [14]. This does not mean pediatric use has not occurred. It means any events have not been reported or have not yet appeared in the public data extract.

The Bottom Line for Parents and Clinicians

Jatenzo is an adult medication. Full stop. No clinical trial has evaluated its safety, efficacy, pharmacokinetics, or dosing in children under 12. The risks of any testosterone exposure in prepubertal children (premature epiphyseal closure, cardiovascular changes, hepatic effects, neuropsychiatric alterations, polycythemia) are well-established from other formulations, and Jatenzo adds the unknown variable of lymphatic oral absorption in pediatric physiology.

If a child under 12 has a confirmed diagnosis requiring testosterone (a rare clinical scenario), injectable testosterone enanthate or cypionate at low doses under pediatric endocrinology supervision remains the evidence-based approach [3]. Parents who encounter Jatenzo during online research should understand that its oral convenience does not translate to pediatric safety. Any clinician considering Jatenzo for a prepubertal patient should first exhaust established pediatric formulations and document the clinical rationale with the rigor that off-label controlled substance prescribing demands.

The Endocrine Society recommends that testosterone therapy in children be managed exclusively by pediatric endocrinologists with experience in disorders of sex development and pubertal disorders [3]. The starting dose for pubertal induction with testosterone enanthate is 50 mg intramuscularly every 4 weeks, increasing by 50 mg increments every 6 to 12 months to a maximum of 200 mg every 2 weeks at full adult replacement [3].